SCHEMBL904760

SCHEMBL904760

CCc1cc(C(=O)OC)ccc1S(=O)(=O)NCc1ccc2c(cnn2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
HTR2A P28223 1/20 0.41
PASK Q96RG2 1/20 0.41
CDK19 Q9BWU1 1/20 0.41
PDE1C Q14123 1/20 0.40
VNN1 O95497 1/20 0.40
CACNA1H O95180 6/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
SMO Q99835 2/20 0.39
ALDH1A1 P00352 3/20 0.38
THRB P10828 2/20 0.38
RECQL P46063 2/20 0.38
KDM4E B2RXH2 1/20 0.38
AR P10275 1/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL904733 0.89 PDE1C (0.43) POLBCCNCCDK8HTR2APASK
SCHEMBL904717 0.89 MAOA (0.43) POLBCCNCCDK8HTR2APASK
SCHEMBL904759 0.85 POLB (0.55) POLBCCNCCDK8HTR2APASK
SCHEMBL904599 0.83 LMNA (0.41) POLBCCNCCDK8HTR2APASK
SCHEMBL904795 0.78 POLB (0.59) POLBCCNCCDK8PDE1CVNN1
SCHEMBL904721 0.77 POLB (0.40) POLBALDH1A1THRBRECQLKDM4E
SCHEMBL30041675 0.76 PDE1C (0.57) CCNCCDK8HTR2APASKCDK19
SCHEMBL1144917 0.76 PDE1C (0.57) CCNCCDK8HTR2APASKCDK19
SCHEMBL904620 0.76 TRPM8 (0.47) CACNA1HMAOBMAOAACHE
SCHEMBL904674 0.75 POLB (0.53) POLBCACNA1HALDH1A1THRBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM6, TRPM5 POLB 4408/4885CCNC 3971/4885CDK8 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.